Shinkai 2021.

Study characteristics
Methods	Single‐blinded RCT
Participants	People with confirmed COVID‐19 (mild/moderate) admitted to 39 centres in Japan
Interventions	Favipiravir, placebo
Outcomes	Time to improvement in four clinical parameters: temperature SpO2 was defined as SpO2 remaining ≥ 96% for at least 24 hours without the use of oxygen therapy; chest imaging was defined as improvement in chest imaging findings taken at least 24 hours after the previous image judged to be the worst; recovery to SARS‐CoV‐2 negative was defined as two consecutive negative results on qualitative tests by nucleic acid amplification separated by at least 24 hours and all adverse events
Notes